SULF1 and SULF2 Role in Cholangiocarcinoma


About this study

Cholangiocarcinoma (CCA) has key similarities with HCC, therefore, we hypothesize that Sulf1 and Sulf2 may also play roles in promotion of CCA progression.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients aged 18 years and older
  • Diagnosed CCA between January 1, 2000 and December 31, 2016. Diagnosis of CCA validated by histopathology or cytologic examination. CCA patients with available data on prognosis and clinical characteristics.
  • Enrolled in IRB 707-03 and/or has (Tissue Microarray) TMA created for IRB 707-03

Exclusion Criteria: 

  • Patients without definite diagnosis of CCA or available clinical data.
  • Younger than 18 years

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lewis Roberts, M.B., Ch.B., Ph.D.

Contact us for the latest status

Contact information:

Nasra Giama D.N.P., R.N.


More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions